This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Maruyama, T. Articles by Kobayashi, T. Search for Related Content PubMed PubMed Citation Articles by Maruyama, T. Articles by Kobayashi, T. Related Collections Pediatric Endocrinology Diabetes and Insulin

Insulin Intervention in Slowly Progressive Insulin-Dependent (Type 1) Diabetes Mellitus

Department of Internal Medicine (T.M.), Saitama Social Insurance Hospital, Saitama 330-0074, Japan; Third Department of Internal Medicine (S.T., N.H., H.S., T.K.), Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi 409-3898, Japan; Department of Internal Medicine (A.S., S.Y.) and Department of Laboratory Medicine (I.T.), Keio University, Tokyo 160-8582, Japan; Department of Internal Medicine (O.F.), Saiseikai Central Hospital, Tokyo 108-0073, Japan; Department of Internal Medicine (A.Kas), Tokyo Denryoku Hospital, Tokyo 160-0016, Japan; Diabetes Center (A.Kan), Chiba Central Medical Center, Chiba 264-0017, Japan; Department of Endocrinology and Metabolism (T.K.), Toranomon Hospital, Tokyo 105-8470, Japan

Address all correspondence and requests for reprints to: Tetsuro Kobayashi, M.D., Ph.D., Third Department of Internal Medicine, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi 409-3898, Japan. E-mail: tetsurou{at}yamanashi.ac.jp.

Objective: We tested the hypothesis that insulin therapy rather than sulfonylurea (SU) treatment is preferable to reverse or preserve β-cell function among patients with slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) or latent autoimmune diabetes in adults.

Methods: This multicenter, randomized, nonblinded clinical study screened 4089 non-insulin-dependent diabetic patients for glutamic acid decarboxylase autoantibodies (GADAb). Sixty GADAb-positive non-insulin-requiring diabetic patients with a 5-yr duration or shorter of diabetes were assigned to either the SU group (n = 30) or the insulin group (n = 30). Serum C-peptide responses to annual oral glucose tolerance tests were followed up for a mean of 57 months. The primary endpoint was an insulin-dependent state defined by the sum of serum C-peptide values during the oral glucose tolerance test (C-peptide) less than 4 ng/ml (1.32 nmol/liter).

Results: The progression rate to an insulin-dependent state in the insulin group (three of 30, 10%) was lower than that in the SU group (13 of 30, 43%; P = 0.003, log-rank). Longitudinal analysis demonstrated that C-peptide values were better preserved in the insulin group than in the SU group. Multiple regression analysis demonstrated that insulin treatment, a preserved C-peptide response, and a low GADAb titer at entry were independent factors in preventing progression to an insulin-dependent state. Subgroup analysis suggested that insulin intervention was highly effective for SPIDDM patients with high GADAb titers [10 U/ml (180 World Health Organization U/ml)] and preserved β-cell function [C-peptide 10 ng/ml (3.31 nmol/liter)] at entry. No severe hypoglycemic episodes occurred during the study.

Conclusions: Insulin intervention to preserve β-cell function is effective and safe for patients with SPIDDM or latent autoimmune diabetes in adults.